The main business of Sannuo Biosensor Co., Ltd. is to use biosensor technology to develop, produce, and sell instant detection products to be listed on the Shenzhen Stock Exchange. The stock is referred to as "Sannuo Biological", and the stock code is 300298.The companys main products are trace blood fast blood glucose tester and test strip of blood sugar detection, which constitutes a blood glucose monitoring system for blood sugar monitoring.
Sannuo Biological has been supported by the National Innovation Fund twice in 2003 and 2008, and is the undertaking unit of the national biomedical engineering high -tech industrialization demonstration project.As one of the most important manufacturers of blood sugar monitoring system products in China, the companys "SXT-1", "Stable", "Anzhong" blood glucose tester and supporting test strips have obtained medical device product registration certificates.The company obtained medical device production licenses after being qualified by Hunan Food and Drug Administration on the spot.In addition, the company has passed ISO: 13485 quality management system certification.In terms of product exports, the companys blood sugar monitoring system products have passed EU CE certification.
The rapid growth of the company depends on the unique profit model.The companys main products include the blood glucose tester and the supporting test bar. The two must be paired.The company adopts the profit model of the instrument occupation market and consumables earning profits. It will occupy the market by providing the blood glucose meter and test bar that ordinary people can afford it. After the instrument is sold, the corresponding test strip shows cumulative growth.In the past three years, the sales of instruments have increased significantly, and the compound growth rate of income is 25%.
The completion of the "Biosensor Production Base" will effectively consolidate and improve the comprehensive competitiveness of the company in the micro -blood glucose tester and supporting blood glucose test test products, improve the production process, improve the companys product quality, solve the problem of insufficient production capacity, and comprehensively improve it.The companys competitive position in the domestic blood glucose monitoring system industry.It helps the company to consolidate the domestic market, open up international markets, expand market share, enhance brand value, develop new products, and further improve its core competitiveness.The "marketing network construction" project can further improve the companys product market coverage, enhance product brand image, strengthen the companys customer service capabilities, and lay the foundation for the company to obtain larger market share and cover a higher -level market.
Sannuo Bio has established the largest and most professional marketing team of the domestic blood glucose testing industry so far. They are widely active in markets such as provinces, cities and counties, and other levels.The rapid and large number of shipments of the Sannuo series of blood glucose meters have led to the continuous and rapid growth of the sales of blood sugar test strips matched. A large number of dealers and pharmacies who have cooperated many years have also received considerable sales returns.
Recently, the science and technology department announced the "Twelfth Five -Year Plan" of Medical Science and Technology Development. The "Planning" proposed that major new drugs, medical devices, and modernization of traditional Chinese medicine are the core to develop a strategic emerging industry of biomedical.Blood glucose instrument -based enterprises based on biosensor technology will benefit from the expansion of the product market under policy support.It is expected that the market capacity of the new blood glucose tester in the next 5 years will be 4.682 billion yuan, and the annual test strip capacity will be 8.163 billion yuan, a total of 12.845 billion yuan. The huge market capacity will provide a strong guarantee for the long -term development of Sannuo creatures.
In the future, Sannuo Bio will continue to be committed to the development and industrialization of POCT products, maintaining the companys leading position in the blood glucose monitoring system industry, leading the scale and marketization of POCT products of diabetes, cardiovascular diseases and infectious diseases.Provide detection tools and information management services for emergency, fast testing and chronic disease management, and form an IoT interaction system for the disease management objects that monitor and evaluate intervention, realize the companys sustainable, healthy and rapid development, and adhere to the "adherence to commitments and dedication to health"Corporate purpose, continuously enhance the value of the company, and maximize the interests of investors and customer value.